A single combined measure of hsCRP, LDL-C, and Lp(a) can predict incident cardiovascular events across a 30-year period, and has potential for extending strategies for primary prevention of atherosclerotic events.
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.